Quality of life in patients with persistent allergic rhinitis treated with montelukast alone or in combination with levocetirizine or desloratadine

Journal of Investigational Allergology and Clinical Immunology

Volumn 18, Issue 5, 2008, Pages 343-349

  Ciebiada, Maciej ^a   Gorska Ciebiada, M ^a   Kmiecik, T ^a   DuBuske, L M ^b   Gorski, P ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Immunology Research Institute of New England   (United States)

Author keywords

Desloratadine; Levocetirizine; Montelukast; Persistent allergic rhinitis; Quality of life

Indexed keywords

DESLORATADINE; LEVOCETIRIZINE; MONTELUKAST; PLACEBO; XYLOMETAZOLINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EVENING DOSAGE; FEMALE; HUMAN; MALE; MONOTHERAPY; PERENNIAL RHINITIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACETATES; ADOLESCENT; ADULT; AGED; CETIRIZINE; CHRONIC DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LEUKOTRIENE ANTAGONISTS; LORATADINE; MALE; MIDDLE AGED; QUALITY OF LIFE; QUINOLINES; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 55449127298     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Woods L, Craig TJ. The importance of rhinitis on sleep, daytime somnolence, productivity and fatigue. Curr Opin Pulm Med. 2006;12(6):390-6.
2. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy. 2001;56(11):1077-80.
3. Meltzer EO, Prenner BM, Nayak A, Desloratadine Study Group. Efficacy and tolerability of once-daily 5 mg desloratadine, an H1 receptor antagonist, in patients with seasonal allergic rhinitis. Clin Drug Invest. 2001;21:25-32.
4. de Blic J, Wahn U, Billard E, Alt R, Pujazon MC. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr Allergy and Immunol. 2005;16(3):267-75.
5. Day JH, Briscoe MP, Rafeiro E, Ratz JD. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the environmental exposure unit (EEU). Int J Clin Pract. 2004;58(2):109-18.
6. Patel P, Philip G, Yang W, Call R, Horak F, LaForce C, Gilles L, Garrett GC, Dass SB, Knorr BA, Reiss TF. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2005;95(6):551-7.
7. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21(1):77-83.
8. Dzaman K, Jadczak M, Rapiejko P, Usowski J, Jurkiewicz D. Life quality analysis based on a self - administered questionnaire in patient with nasal obstruction. Annales UMCS. 2005;90:416-20.
9. Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol. 1996;98:843-5.
10. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:1-99.
11. Chen ST, Lu KH, Sun HL, Chang WT, Lue KH, Chou MC. Randomized placebo controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2-6 yr. Pediatr Allergy Immunol. 2006;17(1):49-54.
12. Van Cauwenberge P. Advances in allergy management. Allergy 2002;57(75):29-36.
13. Potter PC, Paediatric Levocetirizine Study Group. Efficacy and safety of levocetirizine on symptoms and health related quality of life of children with perennial allergic rhinitis: a double blind, placebo controlled randomized clinical trail. Ann Allergy Asthma Immunol. 2005;95(2):175-80.
14. Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J, Van Cauwenberge PB, Van Hammee G, XPERT Study Group. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol. 2004;114(4):838-44.
15. Canonica GW, Bousquet J, Van Hammee G, Bachert C, Durham SR, Klimek L, Mullol J, van Cauwenberge PB, XPERT Study Group. Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Respir Med. 2006; 100(10):1706-15.
16. Ciebiada M, Gorska-Ciebiada M, DuBuske LM, Gorski P. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97(5):664-71.
17. Henz BM. The pharmacologic profile of desloratadine: a review. Allergy. 2001;56 (65):7-13.
18. Ciebiada M, Gorska Ciebiada M, Gorski P. Desloratadine in the treatment of perennial allergic rhinitis. A multicenter study in Poland. Allergy Asthma Immunol. 2002;8(2):101-5.
19. Thomson L, Blaylock MG, Sexton DW, Campbell A, Walsh GM. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy. 2002;32(8):1187-92.
20. Jerazawi E. Effect of levocetirizine on eotaxin-induced eosinophil chemotaxis with and without interleukin 5 priming in vitro. Allergy. 2001;56(68):138.
21. Potter PC. Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites. Allergy. 2003;58:893-9.
22. Ciprandi G, Cirillo I, Vizzaccaro A, Civardi E, Barberi S, Allen M, Marseglia GL. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol. 2005;5(13-14):1800-8.
23. van Adelsberg J, Philip G, Pedinoff AJ, Meltzer EO, Ratner PH, Menten J, Reiss TF, Montelukast Fall Rhinitis Study Group. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy. 2003;58:1268-76.
24. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double blind, placebo controlled trial performed in the fall. Ann Allergy Asthma Immunol. 2002;88(6):592-600.